Search

Search Constraints

You searched for: Author/Creator Dean, Robert A.

Search Results

1. [IC‐P‐043]: EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE. (1st July 2017)

2. [P1–042]: PLASMA PHARMACOKINETICS AND PHARMACODYNAMICS OF SOLANEZUMAB IN MILD AND MODERATE AD PATIENTS. (1st July 2017)

3. [P1–049]: SOLANEZUMAB CENTRAL TARGET ENGAGEMENT AND PHARMACODYNAMIC ACTIVITY IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD: COMPARISON TO EXPEDITION/EXPEDITION 2. (1st July 2017)

4. [P2–002]: EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE. (1st July 2017)

5. [P4–155]: DERIVING A CUT‐OFF FOR THE ELECSYS® β‐AMYLOID (1–42) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER's DISEASE (AD). (1st July 2017)

6. A Phase 2, Placebo‐Controlled Study of the Opioid Receptor Antagonist LY2196044 for the Treatment of Alcohol Dependence. (6th September 2013)

7. Adaptation of the robust method to large distributions of reference values: program modifications and comparison of alternative computational methods. Issue 3 (4th May 2019)

8. Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia. Issue 1 (9th November 2018)

9. Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease. Issue 1 (10th August 2018)